## Edgar Filing: Spark Therapeutics, Inc. - Form 4

Spark Therap	peutics, Inc.									
Form 4	215									
March 18, 20	_								PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIO									3235-0287	
Check this box Washington, D.C. 20549									January 31,	
if no longer subject to Section 16. Form 4 or							Estimated	ated average n hours per		
Form 5 obligation may cont <i>See</i> Instru 1(b).	ns inue. Section 17(	a) of the l	Public U	Jtility Hol	ding Cor		nge Act of 1934, of 1935 or Secti 940	on		
(Print or Type I	Responses)									
1. Name and A Webster Ste	2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer						
			Spark Therapeutics, Inc. [ONCE]				(Check all applicable)			
(Last) (First) (Middle) C/O SPARK THERAPEUTICS, INC., 3737 MARKET STREET,			3. Date of Earliest Transaction (Month/Day/Year) 03/16/2015			Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer				
SUITE 1300			4 70 4							
				Filed(Month/Day/Year) Applicable Lin _X_ Form filed			Applicable Line) _X_ Form filed by	y One Reporting Person		
PHILADEL	PHIA, PA 19104	ł					Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
D . I D		c	c		~ · 11					
Reminder: Rep	ort on a separate line	for each cl	ass of sec	urities benef	Perso inform requir	ons who res nation cont red to resp ays a curre	or indirectly. spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					posed of, or convertible	Beneficially Owner securities)	1		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

## Edgar Filing: Spark Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)	)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Employee Stock Option (right to buy)	\$ 68.45	03/16/2015		A	60,000	<u>(1)</u>	03/15/2025	Common Stock	60,000	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Webster Stephen W C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA, PA 19104			Chief Financial Officer		
Signatures					
/s/ Joseph W. La Barge, attorney-in-fact fo Webster		03/18/2015			
**Signature of Reporting Person			Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% vests March 16, 2016 and the remainder vests in equal quarterly installments over the following three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.